Table 4.
Predicted required LLT for those who completed CR in 2019 (n = 55)
| Moderate intensity statin monotherapy | 4 (7) | 
|---|---|
| High intensity statin monotherapy | 15 (27) | 
| High intensity statin + ezetimibe | 14 (25) | 
| PCSK9i + high intensity statin | 9 (16) | 
| PCSK9i + high intensity statin + ezetimibe | 13 (24) | 
Table 4 displays the predicted LLT required for those who failed to meet their absolute LDL-C targets upon completion of CR in 2019. Values are displayed as count with percentage of column total in brackets